Stocks & Investing
Stocks and Investing
Stocks and Investing
Wed, December 21, 2022
[ Wed, Dec 21st 2022
] - WOPRAI
[ Wed, Dec 21st 2022
] - WOPRAI
[ Wed, Dec 21st 2022
] - WOPRAI
[ Wed, Dec 21st 2022
] - WOPRAI
[ Wed, Dec 21st 2022
] - WOPRAI
[ Wed, Dec 21st 2022
] - WOPRAI
[ Wed, Dec 21st 2022
] - WOPRAI
[ Wed, Dec 21st 2022
] - WOPRAI
[ Wed, Dec 21st 2022
] - WOPRAI
[ Wed, Dec 21st 2022
] - WOPRAI
[ Wed, Dec 21st 2022
] - WOPRAI
[ Wed, Dec 21st 2022
] - WOPRAI
[ Wed, Dec 21st 2022
] - WOPRAI
[ Wed, Dec 21st 2022
] - WOPRAI
[ Wed, Dec 21st 2022
] - WOPRAI
[ Wed, Dec 21st 2022
] - WOPRAI
[ Wed, Dec 21st 2022
] - WOPRAI
[ Wed, Dec 21st 2022
] - WOPRAI
[ Wed, Dec 21st 2022
] - WOPRAI
[ Wed, Dec 21st 2022
] - WOPRAI
[ Wed, Dec 21st 2022
] - WOPRAI
Tue, December 20, 2022
[ Tue, Dec 20th 2022
] - WOPRAI
[ Tue, Dec 20th 2022
] - WOPRAI
[ Tue, Dec 20th 2022
] - WOPRAI
[ Tue, Dec 20th 2022
] - WOPRAI
[ Tue, Dec 20th 2022
] - WOPRAI
[ Tue, Dec 20th 2022
] - WOPRAI
[ Tue, Dec 20th 2022
] - WOPRAI
Kostas Biliouris Upgraded (BEAM) to Buy and Increased Target to $66 on, Dec 20th, 2022
Kostas Biliouris of BMO Capital, Upgraded "Beam Therapeutics Inc." (BEAM) to Buy and Increased Target from $61 to $66 on, Dec 20th, 2022.
Kostas has made no other calls on BEAM in the last 4 months.
There are 3 other peers that have a rating on BEAM. Out of the 3 peers that are also analyzing BEAM, 1 agrees with Kostas's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Richard Law of "Credit Suisse" Maintained at Hold with Decreased Target to $53 on, Tuesday, November 8th, 2022
These are the ratings of the 2 analyists that currently disagree with Kostas
- Samantha Semenkow of "Citigroup" Initiated at Strong Buy and Held Target at $62 on, Tuesday, December 13th, 2022
- Mani Foroohar of "SVB Leerink" Maintained at Buy with Decreased Target to $81 on, Monday, November 7th, 2022
